Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,467 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety Testing Clear all
Completed Not applicable Interventional Results available

Prospective Genotyping For Total Hip or Knee Replacement Patients Receiving Warfarin (Coumadin)

NCT00634907
View directory record Official record
Conditions
Venous Thromboembolism, Bleeding
Interventions
Pharmacogenetic-based warfarin dosing, Usual care warfarin dosing
Genetic · Other
Lead sponsor
Gwen McMillin
Other
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 24, 2026, 2:43 PM EDT
Terminated Phase 4 Interventional

Testing the Safety and Efficacy of Commercial Drug Biktarvy in Subjects Known to Have the 184 Resistance Mutation to a Component in Biktarvy

NCT04040075
View directory record Official record
Conditions
HIV-1-infection
Interventions
Biktarvy Tab
Drug
Lead sponsor
Southampton Healthcare, Inc.
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Oct 24, 2026, 2:43 PM EDT
Not listed Not applicable Interventional

Improving Safety and Quality With Outpatient Order Entry

NCT00243334
View directory record Official record
Conditions
Ambulatory Care Information Systems, Clinical Decision Support Systems
Interventions
Integration of advanced clinical decision support with ambulatory computerized physician order entry
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 18, 2013 · Synced Oct 24, 2026, 2:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Geriatric Acute & Post-acute Care Coordination Program for Fall Prevention in the Emergency Department II

NCT04304495
View directory record Official record
Conditions
Fall
Interventions
Fall Prevention
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
65 Years and older
Enrollment
197 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
3
States / cities
Aurora, Colorado • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 24, 2026, 2:43 PM EDT
Recruiting Not applicable Interventional

Safety and Efficacy of Head-lice Treatments Elimax Green Lotion and Walgreens Lice Killing Shampoo

NCT07191457
View directory record Official record
Conditions
Head Lice
Interventions
Elimax Green Lotion with Emogreen, Walgreens Lice Killing Shampoo
Device · Drug
Lead sponsor
Oystershell NV
Industry
Eligibility
6 Months and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Enid, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 24, 2026, 2:43 PM EDT
Terminated Phase 1 Interventional

Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.

NCT01248858
View directory record Official record
Conditions
Cancer
Interventions
GSK2126458 and GSK1120212
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 24, 2026, 2:43 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Sedation With Dexmedetomidine During Cardiac Catheterization

NCT01072643
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Dexmedetomidine
Drug
Lead sponsor
Aruna Nathan
Other
Eligibility
8 Years to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 24, 2026, 2:43 PM EDT
Completed Not applicable Interventional

Evaluating the Cost Effectiveness of STEADI

NCT05390736
View directory record Official record
Conditions
Accidental Fall
Interventions
Gait and balance assessment, Medication review, Comorbidity review, Fall history, Assessment of feet/footwear, Assessment of visual acuity, Home safety risk assessment, Vitamin D Deficiency
Behavioral
Lead sponsor
National Opinion Research Center
Other
Eligibility
65 Years and older
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 24, 2026, 2:43 PM EDT
Completed Phase 1 Interventional

Safety Study of Chinese Herbal Therapy to Treat Asthma

NCT00601263
View directory record Official record
Conditions
Asthma
Interventions
Anti-Asthma Herbal Medical Intervention (ASHMI)
Drug
Lead sponsor
Xiu-Min Li
Other
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 24, 2026, 2:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Pharmacokinetics and Pharmacodynamics Study of Treatment With CHF 5074 in Healthy Young Male Subjects

NCT00954252
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
CHF 5074, placebo
Drug
Lead sponsor
CERESPIR
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Eatontown, NJ 07724, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 10, 2015 · Synced Oct 24, 2026, 2:43 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis

NCT05413304
View directory record Official record
Conditions
Glioma
Interventions
Pre-operative abemaciclib, Device for Cerebral Fluid Dialysate Collection, Ashion Analytics GEM ExTra, abemaciclib + temozolomide, Temozolomide, Brain MRI, Brain CT, EKG, Chest X-ray, Biopsy/resection
Drug · Device · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 39 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 24, 2026, 2:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluate the Safety and Effectiveness of the Biotrue ONEday for Astigmatism

NCT03681808
View directory record Official record
Conditions
Astigmatism
Interventions
Control, Test
Device
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
13
States / cities
Irvine, California • San Diego, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 24, 2026, 2:43 PM EDT
Not listed Not applicable Interventional

Pilot Testing Decision Making in Aging and Dementia for Autonomy Program in Nursing Homes

NCT05618678
View directory record Official record
Conditions
Dementia, Staff Attitude, Nurse's Role, Nursing Homes
Interventions
DIGNITY, Infection Control
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
State College, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 24, 2026, 2:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study to Evaluate the Contact Sensitizing Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA

NCT02160587
View directory record Official record
Conditions
Surgical Site Infection
Interventions
Chloraprep, 0.9% Physiological Saline, ZuraPrep without IPA
Drug · Other
Lead sponsor
Zurex Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 24, 2026, 2:43 PM EDT
Completed Phase 1 Interventional

Effects of Triiodothyronine (T3) in Ischemic Heart Failure

NCT05384847
View directory record Official record
Conditions
Heart Failure
Interventions
Thyroid hormone T3, Control Group
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 24, 2026, 2:43 PM EDT
Completed Early Phase 1 Interventional

Pyrimethamine as an Inhibitor of NRF2 in HPV-unrelated Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT05678348
View directory record Official record
Conditions
Head and Neck Cancer, Cancer of the Head and Neck
Interventions
Pyrimethamine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 24, 2026, 2:43 PM EDT
Completed Phase 3 Interventional Results available

An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)

NCT02962648
View directory record Official record
Conditions
Iron Deficiency Anemia, Iron Deficiency Anaemia
Interventions
Iron isomaltoside/ferric derisomaltose
Drug
Lead sponsor
Pharmacosmos A/S
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Chula Vista, California • La Mesa, California • Northridge, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 24, 2026, 2:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High Altitude

NCT01794078
View directory record Official record
Conditions
Acute Mountain Sickness and Fatigue
Interventions
Aminophylline 400 mg, Ambrisentan 5 mg, Placebo
Drug · Other
Lead sponsor
Robert J Noveck, M.D.
Other
Eligibility
18 Years to 50 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2015 · Synced Oct 24, 2026, 2:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Early Study of N-Acetylcysteine to Treat Deliberate Self-Harm in Adolescents

NCT01111734
View directory record Official record
Conditions
Deliberate Self Harm
Interventions
N-Acetylcysteine, fMRI
Dietary Supplement · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
13 Years to 21 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 24, 2026, 2:43 PM EDT
Not listed Phase 1Phase 2 Interventional

[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application

NCT05458544
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
[177Lu]Ludotadipep 3.7 GBq
Drug
Lead sponsor
FutureChem
Industry
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Towson, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 24, 2026, 2:43 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

NCT05070858
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Pozelimab + Cemdisiran, Cemdisiran, Placebo, Pozelimab
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
19
States / cities
Scottsdale, Arizona • Irvine, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 24, 2026, 2:43 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT

NCT05327426
View directory record Official record
Conditions
Poliomyelitis
Interventions
Intradermal fractional dose inactivated polio vaccine (fIPV) in combination with recombinant double mutant heat labile toxin, LT(R192G/L211A), (dmLT), Intradermal fractional dose inactivated polio vaccine (fIPV), Monovalent oral poliomyelitis vaccine (mOPV), Sabin strain
Biological
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 45 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 24, 2026, 2:43 PM EDT
Completed Phase 3 Interventional Results available

Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature

NCT01497938
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Medtronic MMT-754 Veo Insulin pump testing Low Glucose Suspend (LGS) feature, Medtronic (NO LGS FEATURE ) using Paradigm® Revel™2.0 Pump
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
17
States / cities
Little Rock, Arkansas • Escondido, California • San Mateo, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Oct 24, 2026, 2:43 PM EDT
Terminated Not applicable Interventional Results available

Providing Optimal PEEP During Mechanical Ventilation for Obese Patients Using Esophageal Balloon

NCT03951064
View directory record Official record
Conditions
Obesity, Morbid, Ventilator-Induced Lung Injury, Respiratory Failure
Interventions
Esophageal balloon, Intervention Spontaneous Breathing Trial (SBT) and Extubation, Control Spontaneous Breathing Trial and Extubation, Intervention Weaning after Tracheostomy, Control Weaning after Tracheostomy
Device · Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Oct 24, 2026, 2:43 PM EDT